

Imke Atreya

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3692664/publications.pdf>

Version: 2024-02-01

29
papers

797
citations

623734

14
h-index

526287

27
g-index

29
all docs

29
docs citations

29
times ranked

1269
citing authors

#	ARTICLE	IF	CITATIONS
1	Epithelial RAC1-dependent cytoskeleton dynamics controls cell mechanics, cell shedding and barrier integrity in intestinal inflammation. <i>Gut</i> , 2023, 72, 275-294.	12.1	18
2	Residual homing of $\hat{1}\pm 4\hat{1}^{27}$ -expressing $\hat{1}^{21}$ regulatory T cells with potent suppressive activity correlates with exposure-efficacy of vedolizumab. <i>Gut</i> , 2022, 71, 1551-1566.	12.1	24
3	Transcriptomes of MPO-Deficient Patients with Generalized Pustular Psoriasis Reveals Expansion of CD4+ Cytotoxic T Cells and an Involvement of the Complement System. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2149-2158.e10.	0.7	7
4	Vedolizumab blocks $\hat{1}\pm 4\hat{1}^{27}$ integrin-mediated T cell adhesion to MAdCAM-1 in microscopic colitis. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210988.	3.2	3
5	Etrolizumab-s Does Not Induce Residual Trafficking of Regulatory T Cells. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1746-1755.	1.9	5
6	Clinical experiences and predictors of success of treatment with vedolizumab in IBD patients: a cohort study. <i>BMC Gastroenterology</i> , 2021, 21, 33.	2.0	10
7	Innate Lymphoid Cells as Regulators of Epithelial Integrity: Therapeutic Implications for Inflammatory Bowel Diseases. <i>Frontiers in Medicine</i> , 2021, 8, 656745.	2.6	16
8	Targeted inhibition of the WEE1 kinase as a novel therapeutic strategy in neuroendocrine neoplasms. <i>Endocrine-Related Cancer</i> , 2021, 28, 605-620.	3.1	1
9	$\hat{1}\pm 4\hat{1}^{27}$ integrin-dependent adhesion of T cells to MAdCAM-1 is blocked by vedolizumab in patients with chronic refractory pouchitis. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110547.	3.2	1
10	Editorial: Loss of Epithelial Barrier Integrity in Inflammatory Diseases: Cellular Mediators and Therapeutic Targets. <i>Frontiers in Medicine</i> , 2021, 8, 813153.	2.6	2
11	Non-classical monocyte homing to the gut via $\hat{1}\pm 4\hat{1}^{27}$ integrin mediates macrophage-dependent intestinal wound healing. <i>Gut</i> , 2020, 69, 252-263.	12.1	80
12	The TLR9 Agonist Cobitolimod Induces IL10-Producing Wound Healing Macrophages and Regulatory T Cells in Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 508-524.	1.3	46
13	ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure. <i>Frontiers in Immunology</i> , 2020, 11, 691.	4.8	15
14	Baseline levels of dynamic CD4+ T cell adhesion to MAdCAM-1 correlate with clinical response to vedolizumab treatment in ulcerative colitis: a cohort study. <i>BMC Gastroenterology</i> , 2020, 20, 103.	2.0	12
15	An Intravital Microscopy-Based Approach to Assess Intestinal Permeability and Epithelial Cell Shedding Performance. <i>Journal of Visualized Experiments</i> , 2020, , .	0.3	1
16	A CCL1/CCR8-dependent feed-forward mechanism drives ILC2 functions in type 2-mediated inflammation. <i>Journal of Experimental Medicine</i> , 2019, 216, 2763-2777.	8.5	48
17	Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease. <i>Frontiers in Pharmacology</i> , 2019, 10, 39.	3.5	25
18	Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy. <i>Journal of Visualized Experiments</i> , 2019, , .	0.3	11

#	ARTICLE	IF	CITATIONS
19	Innate lymphoid cells in intestinal cancer development. <i>Seminars in Immunology</i> , 2019, 41, 101267.	5.6	22
20	Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease. <i>Journal of Visualized Experiments</i> , 2018, , .	0.3	3
21	Similar Inhibition of Dynamic Adhesion of Lymphocytes From IBD Patients to MAdCAM-1 by Vedolizumab and Etrolizumab-s. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1237-1250.	1.9	33
22	Blockade of $\alpha E \beta 7$ integrin suppresses accumulation of CD8 ⁺ and Th9 lymphocytes from patients with IBD in the inflamed gut in vivo. <i>Gut</i> , 2017, 66, 1936-1948.	12.1	99
23	Three-Dimensional Cross-Sectional Light-Sheet Microscopy Imaging of the Inflamed Mouse Gut. <i>Gastroenterology</i> , 2017, 153, 898-900.	1.3	27
24	Molecular pathways driving disease-specific alterations of intestinal epithelial cells. <i>Cellular and Molecular Life Sciences</i> , 2017, 74, 803-826.	5.4	12
25	Clinical Response to Vedolizumab in Ulcerative Colitis Patients Is Associated with Changes in Integrin Expression Profiles. <i>Frontiers in Immunology</i> , 2017, 8, 764.	4.8	42
26	Good Manufacturing Practice-Compliant Production and Lot-Release of Ex Vivo Expanded Regulatory T Cells As Basis for Treatment of Patients with Autoimmune and Inflammatory Disorders. <i>Frontiers in Immunology</i> , 2017, 8, 1371.	4.8	20
27	Differential effects of $\alpha 4 \beta 7$ and GPR15 on homing of effector and regulatory T cells from patients with UC to the inflamed gut in vivo. <i>Gut</i> , 2016, 65, 1642-1664.	12.1	138
28	Rho-A prenylation and signaling link epithelial homeostasis to intestinal inflammation. <i>Journal of Clinical Investigation</i> , 2016, 126, 611-626.	8.2	38
29	Identification and characterization of the specific murine NK cell subset supporting graft-versus-leukemia- and reducing graft-versus-host-effects. <i>Oncolmmunology</i> , 2015, 4, e981483.	4.6	38